Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis  by Radhakrishnan, Jai et al.
Mycophenolate mofetil and intravenous
cyclophosphamide are similar as induction
therapy for class V lupus nephritis
Jai Radhakrishnan1,6, Dimitrios-Anestis Moutzouris2,6, Ellen M. Ginzler3, Neil Solomons4,
Ilias I. Siempos5 and Gerald B. Appel1
1Department of Medicine, Columbia University, New York, New York, USA; 2Division of Nephrology, ‘Evangelismos’
General Hospital, Athens, Greece; 3Department of Medicine, SUNY-Downstate, Brooklyn, New York, USA;
4Vifor Pharma/Aspreva, Victoria, British Columbia, Canada and 5Alfa Institute of Biomedical Sciences, Athens, Greece
Class V lupus nephritis (LN) occurs in one-fifth of biopsy-
proven cases of systemic lupus erythematosus. To study
the effectiveness of treatments in this group of patients,
we pooled analysis of two large randomized controlled
multicenter trials of patients with diverse ethnic and racial
background who had pure class V disease. These patients
received mycophenolate mofetil (MMF) or intravenous
cyclophosphamide (IVC) as induction therapy for 24 weeks,
with percentage change in proteinuria and serum creatinine
as end points. Weighted mean differences, pooled odds
ratios, and confidence intervals were calculated by using a
random-effects model. A total of 84 patients with class V
disease were divided into equal groups, each group had
comparable entry variables but one received MMF and one
received IVC. Within these groups, 33 patients on MMF and
32 patients on IVC completed 24 weeks of treatment. There
were no differences between the groups in mean values for
the measured end points. Similarly, no difference was found
regarding the number of patients who did not complete the
study or who died. In patients with nephrotic syndrome, no
difference was noted between those treated with MMF and
IVC regarding partial remission or change in urine protein.
Hence we found that the response to MMF as induction
treatment of patients with class V LN appears to be no
different from that to IVC.
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Class V lupus nephritis (LN) accounts for 20% of renal
biopsy diagnoses in patients with systemic lupus erythema-
tosus.1–6 Although the risk of progressive renal deterioration
may be lower in class V LN than in the proliferative forms,
it is not negligible.2 Moreover, persistent heavy proteinuria is
associated with the complications of edema, hyperlipidemia,
and hypercoagulability.2 Thus, in symptomatic patients with
class V LN, reduction of proteinuria is desirable. However,
the optimal means to achieve reduction of proteinuria in
such patients remains uncertain. Indeed, most of the studies
on the treatment of patients with class V LN were limited by
the fact that they included both patients with pure class V LN
(ISN class V) and patients with superimposed proliferative
lesions (ISN classes Vþ III and Vþ IV), they were uncon-
trolled, and they did not include a diverse ethnic and
geographic patient population.7
Oral cyclophosphamide with steroids followed by
azathioprine,8 azathioprine with steroids,9 and cyclosporine
with steroids10–12 are among the commonly studied regimens
for the treatment of patients with class V LN. On the other
hand, mycophenolate mofetil (MMF), a potent immunosup-
pressive used in renal transplantation, has recently been used
in many primary and secondary glomerular diseases includ-
ing idiopathic membranous nephropathy.1 Administration of
MMF in patients with LN as both an induction therapy and a
maintenance therapy has been studied in several randomized
controlled trials.13–15 There were few patients with Class V
LN included in these trials. In addition, in uncontrolled
reports that described the treatment of Class V LN with
MMF, a significant proportion of patients had superimposed
proliferative lesions in the kidney biopsy.16,17
To compare the efficacy of MMF versus intravenous
cyclophosphamide (IVC) in severe LN, several large multi-
center trails have recently been completed.18,19 Although an
initial trial of 140 patients from the United States (US study)
suggested a role for MMF in severe lupus renal disease, there
were too few patients with pure Class V LN included to
evaluate the results of comparative therapies in this pattern of
lupus nephropathy.18 A second larger international trial of
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370 patients with severe LN, using the same induction
therapy regimens, also included patients with pure Class V
LN.19 This is a pooled analysis of patients with Class V LN
from these two prospective randomized controlled multi-
center studies with similar entry criteria, comparing 24 weeks
treatment with MMF or IVC as induction treatment.
RESULTS
Baseline characteristics
Out of the 87 patients who had pure Class V LN, 3 patients
were excluded due to protocol violation. Thus, 84 subjects
with Class V LN were included in our pooled analysis; 42
patients were randomized to MMF and 42 patients to IVC
(24 patients in the US study;18 and 60 patients in the ALMS
study19). Baseline characteristics of the patients of the two
studies18,19 are shown in Tables 1a and b.
Dosage of study drugs
The mean dose of MMF was 2653±555 mg/day in the US
study, whereas it was 2828±384 mg/day in the ALMS study.
Of a total of 42 patients receiving MMF, 9 (69%) in the US
study and 24 (83%) in the ALMS study tolerated a dose of
3000 mg/day. Of the 42 patients receiving IVC, 32 (76%)
completed six cycles of IVC (7 in the US study and 25 in the
ALMS study). For patients who initially enrolled in the
studies, the cumulative dose of cyclophosphamide per patient
after 6 months was 4574.4±559 mg/m2 of body surface in the
US study and 4888.3±715 mg/m2 of body surface in the
ALMS study, whereas the mean dose per patient per month
was 762.4±93 mg/m2 of body surface and 816±116 mg/m2
of body surface, respectively (P¼not significant). No data
were available for the IVC dose for the three patients who
were initially enrolled in the US study, but did not complete
the protocol.
Concomitant administration of prednisone and
renin–angiotensin system inhibitors
For patients who completed each study, there were no
significant differences in the dose of prednisone at baseline
(35±23 mg in MMF group vs 54±10 mg in IVC group,
in the US study; and 53±8 mg in MMF group vs 52±10 mg
in IVC group, in the ALMS study), at 12 weeks (18±9 mg in
the MMF group vs 25±15 mg in the IVC group, in the US
study; and 22±6 mg in the MMF group vs 24±6 mg in the
IVC group, in the ALMS study), and at the end of the study
(10±7 mg in the MMF group vs 16±12 mg in the IVC
group, in the US study; and 10±3 mg in the MMF group vs
10±2 mg in the IVC group, in the ALMS study). The starting
dose of prednisone for all patients was not significantly
different between the two groups within each study
(35±24 mg in MMF group vs 49±19 mg in IVC group, in
the US study; and 54±9 mg in MMF group vs 52±11 mg in
IVC group, in the ALMS study). For patients who completed
the 24 weeks of treatment in each study, there was no
difference in the use of renin–angiotensin system inhibitors
between the groups at baseline (in the US study seven
patients (54%) in MMF group and eight patients (73%)
in IVC group; whereas in the ALMS study, 24 patients (83%)
in the MMF group and 25 patients (81%) in IVC group).
Change in urine protein and serum creatinine
In those who completed the full 24 weeks of therapy, subjects
in both groups showed significant improvement in urine
protein excretion at 24 weeks. Results of the two studies18,19
regarding patients who completed the respective studies are
shown in Table 2. Proteinuria (g/day) was also significantly
reduced at 12 weeks compared with baseline in US study
(2.2±1.4, P¼ 0.007 in MMF group and 3.7±3.8, P¼ 0.012
in IVC group) and in ALMS study (2.5±1.7, Po0.001 in
Table 1 | Baseline characteristics of patients of the two studies who (a)a initially enrolled in the studies and (b)b completed the
24 weeks of treatment
Study Group N
Age
(years)
Male
(%)
Cauc
(%)
AA
(%)
Urine
protein
(g/24 h)
Serum
creatinine
(lmol/l)
Serum
albumin
(g/l)
Serum
C3 (g/l)
Serum
C4 (g/l)
Anti-
dsDNA
Nephrotic
(%)
Use of
RAASI (%)
(a)
US MMF 13 31±12 31 15 62 5.2±2.7 72±15 26±7.4 103±31 33±27 0.38±0.65 62 54
IVC 11 37±10 0 18 36 5.8±4.6 61±14 28±6.5 107±39 21±9 0.73±0.79 55 73
ALMS MMF 29 35±12 28 38 24 5±3.3 70±23 29±7.7 99±39 23±19 0.86±0.92 55 83
IVC 31 30±9 13 29 23 5.8±3.7 68±26 26±6.5 89±37 19±11 1±1.1 71 81
(b)
US MMF 8 27±9 63 0 75 3.8±2.2 69±11 28±7.6 120±31 33±16 0.38±0.74 38 63
IVC 7 34±8 0 29 14 6.1±5.3 59±16 28±6.9 118±39 23±11 0.43±0.54 71 71
ALMS MMF 25 34±11 28 40 24 4.9±3.3 70±23 29±8 100±41 24±20 0.76±0.93 56 80
IVC 25 30±9 12 36 12 5.8±4 69±28 26±7 90±39 18±12 1.1±1.2 72 76
AA, African American; Anti-dsDNA, anti-double-stranded DNA; C3, complement 3; C4, complement 4; Cauc, Caucasians; IVC, intravenous cyclophosphamide;
MMF, mycophenolate mofetil; RAASI, renin–angiotensin system inhibitors.
aThere was no statistically significant difference between the characteristics of the two groups within each study, with the exception of the percentage of African American
(AA) patients who completed US study, where statistical significance was noted between the MMF and IVC group (P=0.019).
bThere was no statistically significant difference between the characteristics of the two groups within each study, with the exception of age in ALMS study, where marginal
statistical significance was noted between the MMF and IVC group (P=0.049).
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MMF group and 3.3±2.4, P¼ 0.003 in IVC group). Serum
creatinine (ı`mol/l) was stable at 12 weeks compared with
baseline in US study (74±17, P¼ 0.144 in MMF group and
58±7, P¼ 0.766 in IVC group) and in ALMS study (66±18,
P¼ 0.29 in MMF group and 70±29, P¼ 0.513 in IVC
group).
In the pooled analysis of the two studies, no difference was
found between MMF and IVC group regarding percent
change of urine protein (weighted mean differences (WMD):
3.49%, 95% confidence intervals (CI): 26.88 to 19.9)
(Figure 1) and serum creatinine (WMD: 2.55%, 95% CI:
18.49 to 13.38) (Figure 2).
Withdrawals
Nine patients in the MMF group (five in the US study and
four in the ALMS study) did not complete the protocol (five
patients were withdrawn due to adverse events, one due to
treatment failure, and three self-withdrew). Ten patients in
the IVC group (four in the US study and six in the ALMS
study) did not complete the protocol (three patients due to
adverse events, two due to treatment failure, and five self-
withdrew). There was no difference between the compared
groups regarding the number of patients who withdrew
(P¼ 1.0).
Tolerance of study drugs
Regarding patients who completed the study, in the US study,
all the patients (eight) tolerated the maximal dose of
3000 mg/day. In ALMS study, 22 out of 25 patients who
completed the study tolerated the maximal dose of 3000 mg/
day (88%), with a mean dose of 2880±332 mg/day. For
patients who completed the 24 weeks of ALMS study, the
cumulative dose of cyclophosphamide per patient was
4586±1129 mg/m2 of body surface and the mean dose per
patient per month was 772±194 mg/m2 of body surface,
respectively.
Safety of study drugs
Adverse events in both groups are depicted in Table 3.
Adverse events in the MMF group included gastrointestinal
disorders and infections, whereas in the IVC group cytopenia,
infections, alopecia, and gastrointestinal disorders were the
most common adverse effects. In three patients in the ALMS
study, it was necessary to decrease the dose of MMF to
2000 mg/day. There was one death in each group (P¼ 1.0).
Although the death, which occurred in MMF group, was
attributed to adverse events of MMF, the etiology of the
death in IVC group was unknown and it could not be
definitely attributed to IVC toxicity. Nevertheless, both were
considered as withdrawals due to adverse events and were
included in the respective groups in the flow diagram of the
study.
Subgroup analysis
We performed a subgroup analysis of patients presenting
with nephrotic range proteinuria; out of the 52 patients with
Class V LN who had nephrotic range proteinuria (24 in MMF
group and 28 in IVC group), 40 patients (17 from the US
study and 23 from ALMS study) completed the 24 weeks of
the study. In Table 4, we present the results of the two
studies.18,19 Twelve patients did not complete the study; seven
in the MMF group (two in the US study and five in the
ALMS study)—(four due to adverse effects, two withdrew,
and one due to treatment failure), and five in the IVC group
(one in the US study and four in the ALMS study)—(three
patients withdrew, one due to adverse effects, and one due to
treatment failure). In the pooled analysis of the two studies
(Figure 3), no difference was found regarding partial
remission rates among patients treated with MMF and those
treated with IVC (odds ratio: 1.19, 95% CI 0.29 to 4.91).
In addition, no difference was found in percent urine protein
change (from baseline) between MMF and IVC group
(WMD: 6.81%, 95% CI: 27.03 to 13.42) (Figure 4).
DISCUSSION
By performing a pooled analysis of two randomized
controlled trials that included patients with Class V LN, we
found that administration of high dose corticosteroids and
MMF as induction therapy is as effective as IVC in terms of
improvement in proteinuria and stabilization of serum
creatinine. Similarly, we noted no difference between the
two regimens regarding safety and tolerance. This was also
the case for the subgroup analysis of patients presenting with
nephrotic range proteinuria, that is, MMF was again as
effective and safe as IVC; a fact that adds robustness to the
results of our main analysis.
Table 2 |Main results of the two studies at 24 weeks
Study Group N
Urine
protein
(g/24 h)
Serum
creatinine
(lmol/l)
Serum
albumin
(g/l)
Serum
C3 (g/l)
Serum
C4 (g/l)
Anti-
dsDNA
Nephrotic
(%)
Use of
RAASI
(%)
% Change in
urine
protein
% Change in
serum
creatinine
US MMF 8 1.5±1.1, P=0.007 79±9, P=0.026 34±6 129±37 36±11 0.1±0.3 0 62.5 61±29 16±18
IVC 7 1.6±1, P=0.046 66±25, P=0.283 34±4 130±35 27±15 0.6±1 0 71 71±21 9±18
ALMS MMF 25 1.8±2, Po0.001 63±21, P=0.073 36±8 111±37 30±17 0.4±0.7 12 80 63±29 6±22
IVC 25 2.7±2.4, P=0.001 71±32, P=0.539 34±3 71±33 22±12 1±1.1 32 76 48±51 3±23
Anti-dsDNA, anti-double-stranded DNA; IVC, intravenous cyclophosphamide; MMF, mycophenolate mofetil; RAASI, renin–angiotensin system inhibitors.
There was no statistically significant difference between the characteristics of the two groups within each study, with the exception of anti-dsDNA in the ALMS study, where
statistical significance was noted between the MMF and IVC group (P=0.049).
Change in urine protein and serum creatinine refer to change from the baseline values.
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Patients with Class V LN do not uniformly have a benign
long-term course, and protracted nephrotic syndrome is
associated with an increased risk of significant comorbidities
including hypercoagulability, hyperlipidemia, and cardiovas-
cular disease.2,20 Moreover, the risk of renal insufficiency is
not insignificant and has varied from 47 to 90%.2 Although
it is generally accepted that such patients should receive
treatment, there is a paucity of studies to define the optimal
treatment. Reports on immunosuppressive therapies
for Class V LN, including azathioprine,9 corticosteroids,4
cyclosporine,11 and alkylating agents,21 have suggested that
immunosuppressive therapy is associated with reduction in
proteinuria in a significant number of patients. A recent
randomized controlled trial of prednisone versus cyclospor-
ine versus intravenous cyclophosphamide found less number
of remissions and less sustained remissions with the regimen
containing steroids alone.22
The efficacy and safety of MMF as induction therapy in
severe LN is supported by several randomized studies.23,24 In
Chan et al.’s14 12-month study of 42 patients with Class IV
nephritis, MMF was as effective as oral cyclophosphamide in
inducing remission. In 46 patients with Class IV nephritis,
Hu et al.25 concluded that 6 months of MMF was more
effective than IVC in reducing proteinuria, hematuria, and
autoantibody production. In addition, in a study by Ong
et al.,26 MMF in combination with corticosteroids for 6
months was effective as induction therapy in 44 patients with
Class III and Class IV LN. In a multicenter randomized
controlled induction study of 140 individuals with severe LN,
including patients with both proliferative and membranous
lesions, the toxicity and tolerability profile of MMF com-
pared favorably with cyclophosphamide as induction ther-
apy; moreover, MMF was superior in terms of remission
rates.18 In the ALMS trial of 370 patients, MMF and IVC
were similar in inducing remissions and again had similar
toxicity profiles.19 MMF has also been used successfully as
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Figure 1 |Weighted mean difference of percent change in proteinuria in patients randomized to MMF or IVC
who completed 24 weeks of treatment.
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Figure 2 |Weighted mean difference of percent change in serum creatinine in patients randomized to MMF or IVC
who completed 24 weeks of treatment.
Table 3 | Adverse events in all patients who initially enrolled
in the study
MMF (N=42) IVC (N=42)
Deaths 1 1
Infections
Severe
Tuberculosis 1 0
Pneumonia 1 4
Other
Herpes zoster 2 0
Upper respiratory infections 15 13
Cellulitis 2 1
Tinea of skin, nails 2 2
Oral or vaginal candida 5 3
Urinary tract infections 3 6
Genital herpes 2 0
Gastrointestinal symptoms
Abdominal pain, nausea, vomiting 16 20
Diarrhea 6 4
Other
Leukopenia (o1000/mm3) 0 10
Lymphopenia (o800/mm3) 0 4
Menstrual irregularities 2 4
Alopecia 6 15
Increased liver enzymes 2 4
Interstitial lung disease 2 0
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a maintenance agent for patients whose remissions were
induced by IVC.27
The use of MMF in Class V LN has been reported in small
case series, and the results have been varied. In a study by
Spetie et al.,17 12 patients with pure Class V LN and one with
WHO class V plus III were treated with MMF for a mean
period of 18.8 months. Proteinuria decreased from median
2.26 to 0.66 g (range 0.08–3.85 g). Similarly, Karim et al.28
reported a favorable response to MMF in 10 patients with
Class V LN. However, six of these patients had superimposed
proliferative lesions,19 which are known to be associated with
a worse prognosis in Class V LN patients.29 Finally in a study
by Kapitsinou et al.,30 two of six Class V LN patients (three of
whom had superimposed proliferation) treated with MMF
experienced complete remission by 6 months. Thus, there is
little published information focusing on the treatment of
Class V LN with MMF, and even this is confounded by the
inclusion of patients with mixed membranous and prolif-
erative (ISN Class Vþ III and Vþ IV) lesions. To avoid this
confounding issue, we chose to study only subjects with pure
Class V LN from two randomized, controlled trials with
similar entry criteria. These studies included patients of
diverse ethnic and racial backgrounds.
We found that MMF and IVC were comparable in terms
of remission rates—both complete and partial remission of
proteinuria in patients with nephrotic range proteinuria, and
improvement of clinical parameters such as serum albumin.
The most common adverse events of MMF were gastro-
intestinal, predominantly mild nausea, epigastric pain, loose
stools or diarrhea, whereas infections were not infrequent. In
some studies infections have been less prevalent and less
severe with MMF than those reported with IVC.13 However,
Table 4 | Characteristics of patients with Class V LN and nephrotic-range proteinuria who completed the studies
Study Group N
Age
(years)
Urine protein
at baseline
(g/24 h)
Urine protein
at 24 weeks
(g/24 h)
Change in
urine protein
(%)
Complete
remission (%)
Partial
remission (%)
US MMF 3 23±3 6.02±1.97 1.93±0.66 68±5 0 100
IVC 5 36±5 7.41±5.82 1.83±0.98 70±20 0 80
ALMS MMF 14 34±11 6.74±3.34 2.5±2.4 63±26 7 50
IVC 18 30±8 7.04±4.1 3.29±2.37 44±45 0 55.6
IVC, intravenous cyclophosphamide; MMF, mycophenolate mofetil; RAASI, renin–angiotensin system inhibitors.
There was no statistically significant difference between the characteristics of the two groups within each study, with the exception of age in US study, where statistical
significance was noted between the MMF and IVC groups (P=0.007).
Change in urine protein and serum creatinine refer to change from the baseline values.
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Figure 3 |Odds ratio for partial remission between the MMF group and IVC groups of patients who presented with nephrotic-range
proteinuria.
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Figure 4 |Weighted mean difference of percent change in proteinuria in patients who presented with nephrotic-range
proteinuria, randomized to MMF or IVC, who completed 24 weeks of treatment.
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this was not the case in the ALMS trial.19 In the current
analysis, MMF appeared to be well tolerated despite the
higher doses compared with previous studies. No patient
needed to discontinue MMF because of gastrointestinal
toxicity. There were two deaths, one in each group. It is clear
from these studies that at the high doses used for effective
immunosuppression, MMF does carry considerable risk for
serious infectious and other complications comparable with
IVC. Whether benefits in terms of long-term amenorrhea and
cosmetic changes (alopecia) will make MMF a preferred
agent is unclear at this point.
There were several strengths to our study. It included
robust numbers of patients with pure Class V LN, a
population of diverse ethnic backgrounds, and a control
group treated with an effective regimen of IVC. Although the
patients from the two trials were pooled, there were equal
numbers of patients in each treatment group with similar
baseline characteristics, and a similar induction therapeutic
protocol. Moreover, the use of and doses of inhibitors of
the renin–angiotensin system and steroids were similar in
both groups. Furthermore, the studies included high risk,
difficult to treat patient groups such as African Americans.31
The fact that MMF had comparable efficacy to IVC in this
population lends further support to the role of this drug in
Class V LN.
The limitations of this study include the relatively short
duration of treatment and restriction to induction therapy.
Owing to the short follow-up, this study can only be
considered as evaluating induction therapy, and follow-up is
needed to establish long-term equivalence. The ultimate
complete and partial remission rate would probably have
been much higher with longer treatment on these regimens.
Maintenance therapy is important in view of the significant
relapse rate in Class V LN. For example, the study using
azathioprine reported a cumulative relapse rate of 12% at 36
months and 16% at 60 months.9 It is possible that similar to
Contreras’ trial of maintenance therapy in LN, differences in
outcome may be seen with different maintenance regimens.15
However, by the design of these trials with open therapy for
maintenance in the first study and re-randomization in the
second, it would be impossible to clearly define the role of
maintenance MMF in our populations. Moreover, initial
response to treatment with remission or partial remission has
been shown to correlate with ultimate prognosis in other
lupus populations.32
Another limitation of our study (due to nature of the
analysis) is that only patients who completed 24 weeks of
treatment were included in some parts of the analysis. Most
of the patients who withdrew before 24 weeks were lost to
follow-up making it impossible to analyze their clinical and
laboratory characteristics after withdrawal. It should be
noted, however, that the similar numbers of subjects in each
arm (9 MMF vs 10 IVC) did not reach 24 weeks. In addition,
the number of patients with nephrotic range proteinuria in
our study was rather limited: 8 in the US trial and 32 in the
ALMS trial. Finally, despite our efforts to include all available
evidence on the issue, one might support that our pooled
analysis may lack sufficient power to reveal a potential
difference between the compared regimens regarding their
effectiveness, as power analysis was not performed. However,
in the opinion of some experts, retrospective power analysis
of meta-analysis (especially meta-analysis of subgroups) is a
very controversial issue and should be avoided.33
In conclusion, in our analysis of patients with severe LN,
the combined use of high dose of corticosteroids and MMF
appeared comparable with IVC in inducing remissions of
Class V LN and appeared to be well tolerated. Longer follow-
up of greater numbers of patients and the use of maintenance
therapy in similar populations may further define the role of
MMF in Class V LN.
Underwent randomization, N=84
Eligible patients enrolled, N=84
Assigned to IVC
Received IVC
N=42
Assigned to MMF
Received MMF
N=42
IVC for 24 weeks
N=32
MMF for 24 weeks
N=33
Discontinued
N=9
treatment failure: 1
adverse effects: 5
self-withdrew: 3
Discontinued
N=10
treatment failure: 2
adverse effects: 3
self-withdrew: 5
Included in analysis
N=42
Included in analysis
N=42
Figure 5 | Enrollment of patients, treatment groups. Forty-two patients in each treatment group were included in the analysis of adverse
effects. Only patients who completed the studies (65) were included in at least some of the efficacy analyses.
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MATERIALS AND METHODS
Study design and patient population
Flow diagram of the study is shown in Figure 5. This is a pooled
analysis of twı¨ randomized, controlled, multicenter studies with
similar entry criteria, which included patients with Class V LN
receiving 24 weeks induction treatment with MMF or IVC (24
patients in the US study18 and 60 patients in the ALMS study).19
Class V LN was diagnosed on the basis of World Health Organi-
zation (WHO) or ISN criteria of a locally performed biopsy per-
formed within 6 months of randomization. Protocol details of the
studies are depicted in Table 5. Institutional review boards at each
center approved the study. All individuals gave written informed
consent before randomization.
Treatment protocol
Mycophenolate mofetil was initiated at a dose of 500 mg twice daily,
increased to 1500–2000 mg/day at week 2, and advanced weekly to a
maximum of 3000 mg daily, according to protocol (Table 5). IVC
was given as monthly pulses according to the published National
Institute of Health (NIH) protocol.7 Dosing was modified for nadir
leukocyte count 7–10 days post-infusion p2500/mm3. Patients
received prednisone at a dose of 0.75–1 mg/kg per day according to
the respective protocols of the studies. In the US trial, the new app-
earance or worsening of extrarenal manifestations could be treated
with one 3-day pulse of intravenous methylprednisolone or increa-
sed doses of corticosteroids to a maximum of 2 mg/kg per day.
However, in the ALMS study, subjects requiring treatment with
pulse IV corticosteroids for exacerbations were considered treatment
failures. In addition, patients with lack of response were allowed one
4-week without dose reduction or one dose escalation to the pre-
vious dose for 2 weeks, at any time during the induction phase. In
our analysis, patients requiring IV steroids or increased doses of
steroids were considered treatment failures. However, we found no
patients requiring the above changes in steroid administration. Patients
who did not have an early partial response (at least 30% improvement
in proteinuria and/or azotemia) and crossed to the alternate treatment
arm in the US study were considered treatment failures, as well.
There was no specific protocol regarding the use of rennin–an-
giotensin system inhibitors, but patients were at recommended dose
(as tolerated) of rennin–angiotensin system inhibitors at the
beginning of the study. In ALMS study, the protocol dictated that
rennin–angiotensin system inhibitors might only be taken at stable
doses. Any change in dose or cessation or commencement of therapy
needed to be discussed with the medical monitor. In addition, there
were no specific guidelines by protocol of the studies regarding
blood pressure control, diet, or lipid-lowering medication. In ALMS
study, granisetron HCl (Kytril) could be used to prevent nausea and
vomiting. In addition, minor gastrointestinal adverse effects (such as
Table 5 | Characteristics of the two studies combined focusing on the main differences between the two studies
Study ALMS US
No. of patients with LMN 60 24
Inclusion criteria: SLE meeting four ACR classification criteria (31) and a
renal biopsy documenting lupus nephritis III, IV, or V
For patients with LMN:
Serum creatinine (mg/dl) 41.3 or 41.0 or
Proteinuria (g/24 h) 42 42
Exclusion criteria: Severe concomitant illness precluding immunosuppressive therapy or requiring intravenous antibiotic therapy,
before treatment with MMF, treatment with IVC within 12 months of entry, pregnancy or lactation
Monoclonal antibody therapy within 6 months
(12 months for rituximab) before the entry
Monoclonal antibody therapy within 30 days before
entry
No restriction on renal function Creatinine clearance o30 ml/min, repeated serum
creatinine 43.0 mg/dl
Crossover between arms Not permitted Patients could cross to alternate treatment if they did
not have an early response at 12 weeks
MMF dose 1st week 500 mg b.i.d., 2nd week 750 mg b.i.d.,
increase weekly to max 1000 mg t.i.d.
1st week 500 mg b.i.d., 2nd week 1000 mg b.i.d.,
3rd week 1500 mg b.i.d. (or 1000 mg t.i.d.)
Modification of MMF dose If leukocyte counto1300/mm3 before administration If leukocyte counto3000/mm3 before administration
Pulse steroids Not permitted (considered treatment failures) New appearance or worsening of extrarenal disease
manifestations could be treated with a single 3-day
pulse of IV methylprednisolone or increased
corticosteroids to a maximum 2 mg/kg per day
Steroid dose and tapering Oral prednisolone 0.75–1.0 mg/kg per day (max
60 mg/day). Tapering: by 10 mg/day every 2 weeks to
40 mg/day, then by 5 mg/day every 2 weeks to
10 mg/day. Reductions below 10 mg/day were
allowed after 4 weeks of stable response
Oral prednisone at a dose of 1 mg/kg per day, with
tapering by 10–20% at 1- to 2 -week intervals
C3, C4 levels and ds-DNA
antibody assays
Performed in central laboratory Performed in local laboratories
ACR, American College of Rheumatology; b.i.d., twice daily; dsDNA, double-stranded DNA; LMN, lupus membranous nephritis; MMF, mycophenolate mofetil; SLE, systemic
lupus erythematosus; t.i.d, thrice daily .
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nausea, vomiting, and diarrhea) could be treated symptomatically
(e.g., with loperamide for diarrhea or standard antiemetics such as
metoclopramide or domperidone for nausea and vomiting).
Standard laboratory assessments were performed at entry and at
monthly intervals to assess efficacy and toxicity. As values for anti-
double-stranded DNA antibodies were obtained at local laboratories
for the US study and varied depending on the method applied,
values were converted to scores (on the basis of the respective limits
determined by each laboratory) from 0 to 3, with a score of 0 assig-
ned as negative, 1 to mild abnormality, 2 to moderate abnormality,
and 3 to severe abnormality. In addition, as normal range for serum
C3 and C4 varied in the several laboratories used in the US study,
values were corrected to a single reference range (C3: 0.83–2.01 g/l,
C4: 0.16–0.47 g/l).
Study end points
As primary end point of the combined analysis, we considered the
change (%) of urine protein at 24 weeks. In patients with Class V LN
and nephrotic range proteinuria, complete remission was defined as
urine protein less than 300 mg/day at 24 weeks, whereas partial
remission was defined as urine protein less than 3.5 g/day at 24
weeks plus a 50% reduction from the baseline values. Secondary end
points included changes in renal function, complement compo-
nents, anti-double-stranded DNA titer, and serum albumin.
Statistical analysis
Statistical analysis was performed using SPSS for Mac, version 16.0
(SPSS, Chicago, IL); Review Manager version 5 (Version 5.0.
Copenhagen: The Nordic Cochrane Centre, The Cochrane Colla-
boration, 2008) was used for the meta-analysis. Differences in
baseline characteristics and changes in proteinuria and serum
creatinine between the groups were compared using the two-sample
T-test for continuous variables, and w2-test and Fisher’s exact test for
categorical variables. Pre- and post-treatment values of proteinuria
and serum creatinine within each group were compared using
paired T-test. Reported P-values are two-sided. For patients with
Class V LN and nephrotic range proteinuria, the proportions of
subjects in each treatment group who achieved complete remission
and partial remission at 24 weeks were compared using w2 and
Fisher’s exact test, where appropriate. For ordinal variables,
Kruskal–Wallis test was used. A P-value less than 0.05 (by two-
tailed testing) was considered to indicate statistical significance.
Data are presented as mean±s.d. for continuous variables.
Primary end points for the present pooled analysis were change
(%) of urine protein and serum creatinine. For patients presenting
with nephrotic range proteinuria syndrome, partial remission and
urine protein change were also analyzed. Statistical heterogeneity
among the two studies included in our analysis was assessed by
using both the w2-test and I2-statistic; a w2-test’s P-value lower than
0.10 and an I2 value higher than 50% were defined to note statistical
significance (in case of statistical significance for heterogeneity, the
P-value is provided in the article). Continuous end points were
analyzed using WMD and 95% CI. Pooled odds ratios and
95% CIs for categorical end points were calculated using the
DerSimonian–Laird random effects model.
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